John Paul Leach, MD, MBBS, University of Glasgow, Glasgow, UK, highlights the challenges to epilepsy care brought about by the COVID-19 pandemic. Since many patients do not respond well to initial epilepsy treatment, re-evaluating their diagnosis and reviewing lifestyle influences is a critical factor made difficult by the need for remote assessment. Prof. Leach notes that the rapid introduction of telemedicine services have had some benefits but feels they cannot replace in person care in the future. This interview took place during the European Academy of Neurology 2021 congress.
Prof. Leach has received speaker’s fees and Advisory Board honoraria from UCB Pharma, EISAI, Desitin, GlaxoSmithkline, GW Pharmaceuticals, and Arvelle. There has been an award of an unrestricted Independent Investigator Award from UCB in 2015 to fund a research fellow.